Latest news with #Rznomics
Yahoo
17-05-2025
- Business
- Yahoo
Eli Lilly and Co (LLY): Expands Genetic Hearing Loss Pipeline with $1.3B RNA Therapy Partnership
On May 16, Eli Lilly and Company (NYSE:LLY) announced a partnership with Rznomics to develop RNA-based gene therapies for sensorineural hearing loss, with milestone payments exceeding $1.3 billion. Rznomics will lead early-stage research, while Lilly handles clinical development and commercialization using RNA editing, a reversible alternative to CRISPR. A healthcare professional working on a computer terminal with a patient in the background. The collaboration complements Lilly's existing genetic hearing loss pipeline, including AK-OTOF, a Phase I/II AAV gene therapy targeting OTOF gene mutations. Early data showed hearing restoration in a trial participant within 30 days. Eli Lilly and Company (NYSE:LLY) also signed a $1.4 billion deal with Sangamo Therapeutics for CNS gene therapy in April 2025. Industry focus on genetic hearing loss treatments is growing, with Regeneron's DB-OTO showing measurable hearing improvements in 10 of 11 pediatric patients. Rznomics, which raised $58 million in funding, sees the partnership as a step toward global biotech expansion. CEO Seong-Wook Lee emphasized the potential of precision RNA therapeutics in treating previously untreatable diseases. While we acknowledge the potential of LLY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than LLY and that has 100x upside potential, check out our report about the . READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None.
Yahoo
15-05-2025
- Business
- Yahoo
Rznomics Enters Global Licensing Agreement with Eli Lilly for RNA-editing Therapeutics
Co-development of precision RNA therapeutics for inherited hearing loss treatment SEONGNAM, South Korea, May 15, 2025 /PRNewswire/ -- Rznomics Inc., a South Korea-based biopharmaceutical company specializing in RNA-based therapeutics, announced today that it has entered into a strategic global research collaboration and licensing agreement with Eli Lilly and Company to develop and commercialize novel RNA-editing therapies using Rznomics' proprietary trans-splicing ribozyme platform. The collaboration focuses on the discovery and development of RNA-editing therapeutics for sensorineural hearing loss. Rznomics will conduct early-stage research according to the jointly approved research plans, while Lilly will assume responsibility for further development and commercialization. If Lilly exercises all available options under the agreement, the total deal value could reach more than $1.3 billion, as well as separate royalties on product sales. In line with the mutual understanding between the two companies, the upfront payment was not disclosed. "We are thrilled to collaborate with Lilly, a global leader in pharmaceutical innovation," said Dr. Seong-Wook Lee, CEO of Rznomics. "This partnership validates our trans-splicing ribozyme platform and opens the door to treating previously intractable diseases with precision RNA therapeutics. Together with Lilly, we aim to accelerate the development of transformative therapies for patients around the world." This partnership marks a significant milestone for Rznomics as it seeks to expand its presence in the global biotech arena. For Lilly, the deal aligns with its broader strategy to build a leading RNA therapeutics pipeline and address high unmet needs in hearing loss and other therapeutic areas. About Rznomics Rznomics is a clinical-stage biopharmaceutical company based in South Korea focused on developing RNA-based gene therapies. The company's proprietary trans-splicing ribozyme platform enables precise RNA editing and has broad applicability across multiple indications. For more information, please visit ContactYonsoo JeongBusiness Development / Associate ManagerEmail: ysjeong@ Logo - View original content to download multimedia: SOURCE Rznomics Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
